Modalis Therapeutics advances a novel gene therapy for LAMA2-CMD
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
LAMA2-France and Partners launch landmark LAMA2-CMD natural history study in France. The first French natural history study focused on LAMA2-CMD…
SEAL Therapeutics was established in late 2021 by Prof. Markus Rüegg, Dr. Judith Reinhard, both from the Biozentrum, and Dr.…
Heavyweight kickboxing world champion Rico Verhoeven met up with some of the LAMA2-CMD family in The Netherlands last December 2023. …
Dr Reghan Foley has recently started a new research project in collaboration with the University College Cork / Cork’s University…
Dr. Dwi Kemaladewi and her team at the University of Pittsburgh have been diligently working on the development of a…